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Paracoccidioidomycosis (PCM) is a systemic infection caused by the fungus Paracoccidioides brasiliensis and
is believed to be the leading cause of fungal pulmonary infection. In this study, we used an inhibition
enzyme-linked immunosorbent assay to diagnose pulmonary PCM based on the detection of 43-kDa and
70-kDa molecules in bronchoalveolar lavage fluids. The results were compared with results obtained by
classical methods for antibody detection.
Paracoccidioidomycosis (PCM) is a systemic endemic myco-
sis caused by the dimorphic fungus Paracoccidioides brasiliensis
that affects rural workers in Latin American countries (1, 6, 9).
It has a wide spectrum of clinical manifestations, ranging from
mild pulmonary lesions to severe disseminated forms involving
many organs, especially the mucosae, skin, lymph nodes, adre-
nals, and central nervous system (6, 9). The primary pulmonary
infection is unapparent or oligosymptomatic in most cases, and
individuals may remain infected throughout their lives without
ever developing PCM. In most cases, symptomatic patients
develop the disease years after acquiring the infection as a
result of reactivation of the quiescent foci (chronic form) (3, 9,
10). Clinical findings in these patients generally include severe
pulmonary involvement, followed by extrapulmonary dissemi-
nation. In PCM, lung destruction involves the alveoli, intersti-
tium, and bronchial tree, resulting in fibrosis, ventilatory dys-
function, and hypoxemia (22). Tobo´n et al. (23) recently
reported that late diagnosis and disseminated lung involve-
ment are two conditions associated with a higher rate of pul-
monary sequelae.
Definitive diagnosis of pulmonary PCM is based on the
visualization of fungal elements characteristic of P. brasiliensis
in biopsy material, respiratory secretion, or sputum culture.
However, processing respiratory secretion for direct examina-
tion is time-consuming. Culture is difficult because sputum is
contaminated with bacteria and other yeasts such as Candida
sp. that inhibit the growth of P. brasiliensis, a fastidious organ-
ism, and bronchoscopy and lung biopsy may be difficult to
perform in patients with severe respiratory dysfunction. Hence,
serological methods based on antibody or antigen detection
may be useful tools for diagnosis of the disease. Marques-da-
Silva et al. (15–18) recently described an antigen detection
assay (the inhibition enzyme-linked immunosorbent assay [inh-
ELISA]) for the gp43 and gp70 molecules of P. brasiliensis with
good potential for use in diagnosis and follow-up of patients
with PCM. The detection of P. brasiliensis antigens in body
fluids might facilitate early diagnosis of PCM even in patients
with pulmonary involvement.
In the present study, gp43 and gp70 antigens of P. brasiliensis
were detected in bronchoalveolar lavage (BAL) fluid sam-
ples from patients with pulmonary PCM using an inh-
ELISA. The results were compared with those obtained for
anti-P. brasiliensis antibodies detected by immunodiffusion
(ID) tests and ELISA.
BAL fluid and serum samples were obtained from 27 pa-
tients with pulmonary PCM. Patients were selected based on
clinical, serological, and chest roentgenogram findings as well
as on direct examination of sputum, in which characteristic P.
brasiliensis multibudding yeast cells were seen in all patients.
The patients enrolled in this study were from Hospital Sa˜o
Paulo, Sa˜o Paulo Federal University (UNIFESP), and Hospi-
tal das Clı´nicas, State University of Campinas (UNICAMP),
Campinas, Sa˜o Paulo, Brazil. All patients were male, with an
average age of 46 years. They were subjected to bronchoalveo-
lar lavage procedures. None were suffering from AIDS or
other profoundly immunosuppressive conditions. Each lavage
was performed with five 20-ml aliquots of preservative-free
normal saline, and lavage fluids were then centrifuged at
2,500 g for 10 min in a tabletop centrifuge to prepare sedi-
ments for direct examination and cultures. The supernatants
were stored at 4°C and heated to 56°C for 30 min before being
tested for antigens. The cellular sediment was separated for
direct examination with 30% KOH (characteristic P. brasilien-
sis multibudding yeast cells were visualized in all sediments)
and for culture, but no growth was obtained. In addition, se-
rum samples from patients were tested for anti-P. brasiliensis
antibodies (immunodiffusion and ELISA) and for specific P.
brasiliensis antigens (inh-ELISA). Control groups included 10
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BAL fluid samples from patients with noninfectious diseases
and 10 from patients with other infectious diseases such as
tuberculosis. The study was evaluated and approved by the
Ethics Committee of the Federal University of Sa˜o Paulo.
P. brasiliensis B-339 (ATCC 200273) was obtained from the
culture collection of the Cell Biology Discipline, Federal Uni-
versity of Sa˜o Paulo, and transformed to the yeast phase; exoan-
tigen was produced according to the method of de Camargo et al.
(4, 5), and gp43 and gp70 antigens were purified from this
exoantigen (20, 21). Protein content was determined by the
Bradford method (2). Anti-gp43 and anti-gp70 monoclonal
antibodies (MAbs) were supplied by R. Puccia (21) and D.
Mattos Grosso (20), respectively.
inh-ELISA was performed as previously described (11, 15).
Aliquots of BAL fluid and serum samples (200 l) were mixed
with an equal volume of 0.1 M EDTA (Sigma), pH 7.2, and
boiled at 100°C for 5 min. After cooling, tubes were centri-
fuged at 13,000 g for 30 min, and the supernatants were used
for the test. First, a standard inhibition curve was prepared by
adding known concentrations of gp43 or gp70 to a pool of
normal human sera or BAL fluid controls in different plates
(inhibition standards) (11, 15). The inhibition reaction oc-
curred when constant aliquots of anti-gp43 or anti-gp70 MAbs
were mixed with the inhibition standards, PCM patients’ sera
or BAL fluid samples, and normal human sera and BAL fluid
control samples. Samples were then plated on a previously
blocked microtiter plate (inhibition plate) and incubated over-
night at 4°C. The reaction plate was coated with gp43 or gp70
and incubated overnight at 4°C. Free sites on the polystyrene
were blocked with 5% skim milk in phosphate-buffered saline
(PBS)–Tween 20, and samples from each well in the inhibition
plate (containing a mixture of MAb [anti-gp43 or anti-gp70]
bound to circulating antigen and free MAb) were transferred
to the respective wells in the reaction plate. The plate was
washed, probed with goat anti-mouse immunoglobulin–peroxi-
dase conjugate, and developed with a chromogenic substrate as
previously described (11, 15). Optical density (OD) readings at
492 nm were then plotted on a standard curve constructed
from the data derived from MAb titration with the inhibition
standards. The antigen concentrations in the patients’ BAL
fluid and serum samples were calculated with a regression
model constructed with the reciprocal values of fixed concen-
trations of gp43 or gp70 and the OD values. All tests were
performed in duplicate. All specimens included here had been
tested previously when they were first obtained and were tested
again using the same technique in this study. Inhibition stan-
dard curves were performed in duplicate for at least four in-
dependent assays. Data were statistically analyzed using the
Stata 7.0 program for Windows 98/95/NT (Stata Corporation,
College Station, TX), and specificity and sensitivity were ana-
lyzed using the receiver operator characteristic (ROC) curve.
The sensitivity of the test ranged from 0.001 to 30 g/ml.
ID tests were performed with BAL fluid samples and serum
samples at the time of diagnosis as previously described (4).
For the ELISAs, microtiter plates (Costar) were coated with
100 l of purified gp43 or gp70 (500 ng/well), diluted in 0.06 M
carbonate-bicarbonate buffer, pH 9.6, and incubated for 2 h at
37°C and overnight at 4°C. The plates were washed three times
with PBS-Tween 20 (0.05%), and free sites were blocked with
5% skim milk in PBS-Tween (200 l/well) for 2 h at 37°C.
After three washes, 100 l of BAL fluid samples (1:50 to
1:51,200 dilution) from each patient was added to each well,
and the plates were incubated at 37°C for 1 h. Plates were then
washed again, 100 l of peroxidase-labeled goat anti-human
immunoglobulin (1:1,000 dilution; Sigma) was added to each
well, and the plates were incubated for 1 h at 37°C. After 3
washes, the reaction was developed by adding 100 l of a
mixture of O-phenylenediamine (0.2 mg/ml; Sigma) and
0.05% (vol/vol) H2O2 in 0.1 M citrate buffer, pH 4.5. After
8 min of incubation in the dark, the reaction was stopped
with 50 l of 4 N H2SO4. OD was measured at 492 nm using
an ELISA microplate reader (Titertek Multiskan MCC/340).
gp43 and gp70 antigens in BAL fluid were detected by pre-
paring a standard inhibition curve and determining the cutoff
values (0.23 g/ml for gp43 and 0.21 g/ml for gp70) using an
ROC curve. BAL samples with concentrations above these
values were considered positive. gp43 and gp70 were detected
in all BAL fluid samples (100%). The mean antigen concen-
tration found for gp43 (9.38 g/ml) was significantly higher
than that for gp70 (4.37 g/ml, P 0.0001). BAL fluid samples
from individuals with diseases other than PCM gave negative
results (Table 1).
gp43 and gp70 were detected in sera by preparing a standard
inhibition curve and determining the cutoff values (0.23 g/ml
for gp43 and 0.21 g/ml for gp70) using an ROC curve. Sam-
ples with concentrations above these values were considered
positive. gp43 (mean, 15.53 g/ml) and gp70 (mean, 7.86 g/
ml) antigens were detected in all of the patients’ sera (P 
0.0001).
None of the 27 BAL fluid samples were positive for P.
brasiliensis crude exoantigen in immunodiffusion tests. How-
ever, ID tests showed that 85.18% of the sera were positive,
with antibody titers ranging from 1:8 to 1:64. When tested by
ELISA, all BAL fluid samples (100%) had anti-gp43 and
anti-gp70 antibodies, with titers ranging from 1:50 to 1:400
(Table 1).
Detection of circulating antigen is a useful approach for
serodiagnosis in some invasive fungal diseases (7, 8, 14, 19) and
may also be an alternative tool for diagnosing PCM patients.
Gome´z et al. (11, 12) were the first researchers to use mono-
clonal antibodies to detect an 87-kDa circulating antigen in
PCM and achieved a sensitivity of 80.4%. Marques-da-Silva
et al. (15–18) recently described an antigen detection assay
(inh-ELISA) for P. brasiliensis gp43 and gp70 molecules
with good potential for diagnosis and follow-up of patients
with PCM.
PCM is acquired either by inhalation of mycelial propagules
of the fungus in nature or by reactivation of latent foci of
infection. Pulmonary involvement is characteristic of PCM,
and BAL fluid would accordingly be expected to contain anti-
gens. In other pulmonary diseases, such as histoplasmosis,
Wheat et al. (24) found elevated levels of Histoplasma antigens
in BAL fluid in 19 (70.3%) of 27 cases. Graybill et al. (13) also
reported the presence of Histoplasma antigens in BAL fluid of
mice with experimentally induced histoplasmosis.
In the present study, P. brasiliensis gp43 and gp70 were
detected in all BAL fluid samples from patients with pulmo-
nary PCM, with mean antigen concentrations of 9.38 g/ml
and 4.37 g/ml, respectively. Our results suggest that monitor-
ing specific antigens of P. brasiliensis in BAL samples may be
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helpful in determining a diagnosis of pulmonary PCM, partic-
ularly when the infection is in its initial stage. Since antigen
values for gp43 were always higher than those found for gp70,
assaying only for gp43 may prove sufficient for that purpose.
No antibodies were detected in BAL fluids when tested by ID,
whereas antibodies against both antigens were detected by
ELISA, although the titers were low. However, when sera from
these patients were tested by ID, 85.18% of them reacted
positively, with titers ranging from 1:8 to 1:64. Despite the
limited number of patients in this study, the data suggest that
antigen detection in BAL by inh-ELISA or the detection of
specific antibodies by ELISA may be equally sensitive in iden-
tifying pulmonary PCM. The fact that gp43 and gp70 antigens
were detected in the sera of 100% of these patients indicates
that this test, as well as the detection of antigens in BAL fluid,
has a role to play in the diagnosis of patients with suspected
pulmonary PCM, diffuse pulmonary infiltrates, or unexplained
febrile illnesses. However, antibody detection by ELISA as a
routine procedure is less cumbersome and time-consuming
than antigen detection. Hence, testing of BAL samples for
antigens would be recommended only when a suspected pa-
tient has either negative or inconsistent results for antibody
detection or negative results in the direct examination of spu-
tum or when sera of suspected patients are negative by ID.
Our results show that P. brasiliensis antigen detection in
BAL fluid is a valuable tool for diagnosis of pulmonary PCM.
Nevertheless, the limited clinical and radiological information
available for the small number of patients enrolled in our study
proscribed the possibility of establishing a correlation between
antigen levels and the severity of the disease.
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